Introducing the protein into human melanoma cells was shown to inhibit TNF, IL-1, TLRs, and TNF receptor-associated factor 2- (TRAF2-) induced NF-κB activation, thereby restoring the SAPK or NF-κB response to TNF activation [75]. This evidence concerns the gene NFKB1 and melanoma.